Patents by Inventor Rudolf Fahrig

Rudolf Fahrig has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Uracil derivatives and use thereof
    Patent number: 9181199
    Abstract: Disclosed are uracil derivatives of the formula (I): wherein R1, R2, R3, and X are as defined herein, and use thereof as therapeutic agents. The uracil derivatives are used in particular together with a cytostatic agent for suppressing or reducing resistance building up on cytostatic treatment.
    Type: Grant
    Filed: June 25, 2009
    Date of Patent: November 10, 2015
    Assignee: RESprotect GmbH
    Inventors: Rudolf Fahrig, Kurt Eger, Martin Fuhrer, Nicole Heinze, Matthias Klemm, Jorg-Christian Heinrich
  • Nucleosides for suppressing or reducing the development of resistance in cytostatic therapy
    Patent number: 8492537
    Abstract: The invention relates to special nucleosides, for example, a nucleoside of the formula I, wherein R1-R5 are as described herein, and also to drugs which contain these nucleosides. Furthermore, the invention relates to the use of such nucleosides in a method for suppressing or reducing the formation of resistance in the case of cytotstatic treatment of a cancer patient.
    Type: Grant
    Filed: August 13, 2007
    Date of Patent: July 23, 2013
    Assignee: RESprotect GmbH
    Inventors: Rudolf Fahrig, Dieter Lohmann, Andreas Rolfs, Henrik Dieks, Janek Teubner, Jorg-Christian Heinrich
  • URACIL DERIVATIVES AND USE THEREOF
    Publication number: 20110166096
    Abstract: Disclosed are uracil derivatives of the formula (I): wherein R1, R2, R3, and X are as defined herein, and use thereof as therapeutic agents. The uracil derivatives are used in particular together with a cytostatic agent for suppressing or reducing resistance building up on cytostatic treatment.
    Type: Application
    Filed: June 25, 2009
    Publication date: July 7, 2011
    Applicant: RESPROTECT GMBH
    Inventors: Rudolf Fahrig, Kurt Eger, Martin Führer, Nicole Heinze, Matthias Klemm, Jörg-Christian Heinrich
  • NUCLEOSIDES FOR SUPPRESSING OR REDUCING THE DEVELOPMENT OF RESISTANCE IN CYTOSTATIC THERAPY
    Publication number: 20100227834
    Abstract: The invention relates to special nucleosides, for example, a nucleoside of the formula I, wherein R1-R5 are as described herein, and also to drugs which contain these nucleosides. Furthermore, the invention relates to the use of such nucleosides in a method for suppressing or reducing the formation of resistance in the case of cytostatic treatment of a cancer patient.
    Type: Application
    Filed: August 13, 2007
    Publication date: September 9, 2010
    Applicant: RESprotech GmbH
    Inventors: Rudolf Fahrig, Dieter Lohmann, Andreas Rolfs, Henrik Dieks, Janek Teubner, Jörg-Christian Heinrich
  • Use of 5-substituted nucleosides for reinforcing the apoptotic effect of cytostatic drugs
    Patent number: 7713948
    Abstract: The invention relates to the use of at least one overexpression inhibitor of DNA repair genes and oncogenes for producing a drug to increase the apoptotic effect of cytostatics after chemotherapy.
    Type: Grant
    Filed: November 20, 2003
    Date of Patent: May 11, 2010
    Assignee: Resprotect GmbH
    Inventors: Rudolf Fahrig, Joerg-Christian Heinrich, Georg Krupitza
  • METHOD OF TREATING CANCER BY ADMINISTRATION OF 5-SUBSTITUTED NUCLEOSIDES
    Publication number: 20090068286
    Abstract: The invention relates to methods of administration of at least one overexpression inhibitor of DNA repair genes and/or oncogenes (e.g., (E)-5-(2-bromovinyl)-2?-deoxyuridine (BVDU), or a prodrug, or salt thereof) to increase the cytotoxic effect of a cytostatic or cytotoxic chemotherapeutic agent during and/or after chemotherapy, e.g., in the treatment of cancer.
    Type: Application
    Filed: September 11, 2007
    Publication date: March 12, 2009
    Applicant: RESprotect, GmbH
    Inventors: Rudolf FAHRIG, Joerg-Christian Heinrich
  • Use of 5-substituterd nucleosides for reinforcing the apoptotic effect of cytostatic drugs
    Publication number: 20060178338
    Abstract: The invention relates to the use of at least one overexpression inhibitor of DNA repair genes and oncogenes for producing a drug to increase the apoptotic effect of cytostatics after chemotherapy.
    Type: Application
    Filed: November 20, 2003
    Publication date: August 10, 2006
    Inventors: Rudolf Fahrig, Joerg-Christian Heinrich, Georg Krupitza
  • Utilization of 5? substituted nucleosides for resistance formation in cytoclastic treatment, and drug containing these nucleosides, polymers, methods of use and compositions
    Patent number: 6589941
    Abstract: The invention relates to a method of producing a composition and to a composition for preventing or reducing formation of resistance in cytostatic treatment comprising combining BVDU, a salt thereof or BVDU in protected form or in prodrug form with at least one cytostatic agent in order to prevent or reduce the formation of resistance during cytostatic treatment. The present invention is also directed to a method of reducing resistance in cytostatic treatment comprising delivering therapeutically-effective amount of at least one cytostatic agent and a therapeutically effective amount of BVDU, a salt thereof, or BVDU in protected form or in prodrug form.
    Type: Grant
    Filed: March 7, 2000
    Date of Patent: July 8, 2003
    Assignee: Resprotect GmbH
    Inventors: Rudolf Fahrig, Angela Steinkamp-Zucht